🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "huge turning point" in the battle against increasingly resistant strains of the bacteria, according to scientists.

A Worldwide Health Concern

Cases of gonorrhoea are on the rise worldwide, with estimates suggesting in excess of 82 million new cases annually. Particularly high rates are reported in Africa and countries within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. In England, cases have reached a historical peak, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary advancement in the context of increasing worldwide cases, escalating drug resistance and the very limited available drugs at this time.”

Medical experts are particularly alarmed about the increase in antibiotic-resistant strains. The global health body has listed it as a "high-priority threat". Ongoing monitoring revealed that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Therapies Receive Authorization

One new antibiotic, alternatively called Nuzolvence, was approved by the American regulatory agency in December for use against gonorrhoea. This infection can lead to major issues, including the inability to conceive. Researchers believe that focused deployment of this new drug will help delay the spread of drug resistance.

Another new antibiotic, originating from the drugmaker GSK, gained clearance in the same week. This medication, which is additionally indicated for UTIs, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment was the result of a unique collaborative effort for medication research. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to bring it to fruition.

“This authorization signifies a significant shift in the management of superbug gonorrhoea, which previously has been outpacing antibiotic development.”

Research Study Results and Worldwide Availability

Based on findings released by a major medical journal, zoliflodacin cured the vast majority of uncomplicated infections. This puts it on an equal footing with the existing first-line therapy, which combines a dual-drug approach. The research included nearly 1,000 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, GARDP has the authority to license and sell the drug in a wide range of developing nations.

Clinicians treating patients have expressed positive views. Access to a single-dose, oral treatment of this kind is hailed as a "critical tool" for gonorrhoea control. This is deemed crucial to reduce the burden of the disease for patients and to halt the transmission of highly drug-resistant gonorrhoea globally.